Patents by Inventor Jong Gill

Jong Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130041274
    Abstract: Techniques are provided for detecting and distinguishing stroke and cardiac ischemia based on electrocardiac signals. In one example, the device senses atrial and ventricular signals within the patient along a set of unipolar sensing vectors and identifies certain morphological features within the signals such as PR intervals, ST intervals, QT intervals, T-waves, etc. The device detects changes, if any, within the morphological features such as significant shifts in ST interval elevation or an inversion in T-wave shape, which are indicative of stroke or cardiac ischemia. By selectively comparing changes detected along different unipolar sensing vectors, the device distinguishes or discriminates stroke from cardiac ischemia within the patient. The discrimination may be corroborated using various physiological and hemodynamic parameters. In some examples, the device further identifies the location of the ischemia within the heart.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 14, 2013
    Applicant: PACESETTER, INC.
    Inventors: Jong Gill, Rupinder Bharmi, Edward Karst, Ryan Rooke, Riddhi Shah, Fujian Qu, Gene A. Bornzin, Taraneh Ghaffari Farazi, Euljoon Park
  • Patent number: 8295918
    Abstract: Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: October 23, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Stuart Rosenberg, Cecilia Q. Xi, Yelena Nabutovsky, Brian J. Wenzel, Jong Gill, William Hsu
  • Publication number: 20120239104
    Abstract: A method is provided for trending heart failure based on heart contractility information comprises measuring cardiogenic impedance (CI) measurements along at least a first vector through a heart over a period of time. The method determines contractility estimates from the CI measurements, the contractility estimates relating to contractility of the heart. The method further obtains physiologic and/or surrogate signals representing estimates for or direct measurements of at least one of cardiac volume and pressure of the heart when the CI measurements were obtained. The method identifies correction factors based on the physiologic and/or surrogate signals and applies the correction factors to the contractility estimates to produce contractility trend values over the period of time.
    Type: Application
    Filed: March 16, 2011
    Publication date: September 20, 2012
    Applicant: PACESETTER, INC.
    Inventors: Stuart Rosenberg, Cecilia Qin Xi, Jong Gill, Brian Jeffrey Wenzel, Yelena Nabutovsky, William Hsu
  • Patent number: 8265739
    Abstract: Techniques are provided for use in a pacemaker or implantable cardioverter/defibrillator (ICD) for distinguishing cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals sensed within a patient, such as hypoglycemia, hyperglycemia or other systemic conditions. In one example, the device detects changes in morphological features of cardiac signals indicative of possible cardiac ischemia within the patient, such as changes in ST segment elevation within an intracardiac electrogram (IEGM). The device determines whether the changes in the morphological features are the result of spatially localized changes within a portion of the heart and then distinguishes cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals based on that determination. In another example, the device exploits the interval between the peak of a T-wave (Tmax) and the end of the T-wave (Tend).
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: September 11, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Peter Boileau, Xiaoyi Min, Jong Gill, Rupinder Bharmi, Joseph J. Florio, Michael E. Benser, Gene A. Bornzin
  • Publication number: 20120221069
    Abstract: Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals.
    Type: Application
    Filed: February 25, 2011
    Publication date: August 30, 2012
    Applicant: PACESETTER, INC.
    Inventors: Stuart Rosenberg, Cecilia Qin Xi, Yelena Nabutovsky, Brian Jeffrey Wenzel, Jong Gill, William Hsu
  • Publication number: 20120221066
    Abstract: Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals.
    Type: Application
    Filed: February 25, 2011
    Publication date: August 30, 2012
    Applicant: PACESETTER, INC.
    Inventors: Stuart Rosenberg, Cecilia Qin Xi, Yelena Nabutovsky, Brian Jeffrey Wenzel, Jong Gill, William Hsu
  • Publication number: 20120215275
    Abstract: Embodiments of the present invention are directed to implantable systems, and methods for use therewith, that monitor and modify a patient's arterial blood pressure without requiring an intravascular pressure transducer. In accordance with an embodiment, for each of a plurality of periods of time, there is a determination one or more metrics indicative of pulse arrival time (PAT), each of which are indicative of how long it takes for the left ventricle to generate a pressure pulsation that travels from the patient's aorta to a location remote from the patient's aorta. Based on the one or more metrics indicative of PAT, the patient's arterial blood pressure is estimated. Changes in the arterial blood pressure are monitored over time. Additionally, the patient's arterial blood pressure can be modified by initiating and/or adjusting pacing and/or other therapy based on the estimates of the patient's arterial blood pressure and/or monitored changes therein.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 23, 2012
    Applicant: PACESETTER, INC.
    Inventors: Brian Jeffrey Wenzel, Michael E. Benser, Taraneh Ghaffari Farazi, Timothy A. Fayram, Edward Karst, Allen Keel, Wenbo Hou, Jong Gill
  • Publication number: 20120215117
    Abstract: In specific embodiments, a method for estimating a patient's central arterial blood pressure (CBP) for use with an implantable system, comprises (a) using an implanted sensor at a first site to obtain a first signal indicative of changes in arterial blood volume at the first site, the first site being along one or more peripheral arterial structures of the patient, (b) using an implanted sensor at a second site to obtain a second signal indicative of changes in arterial blood volume at the second site, the second site being a distance from the first site downstream along an arterial path of the peripheral arterial structure of the patient, and (c) using implanted electrodes to obtain a signal indicative of electrical activity of the patient's heart.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 23, 2012
    Applicant: PACESETTER, INC.
    Inventors: Edward Karst, Brian Jeffrey Wenzel, Timothy A. Fayram, Allen Keel, Wenbo Hou, Taraneh Ghaffari Farazi, Jong Gill
  • Publication number: 20120197149
    Abstract: Techniques are described for detecting ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. Ischemia is detected based on a shortening of the interval between the QRS complex and the end of a T-wave (QTmax), alone or in combination with a change in ST segment elevation. Alternatively, ischemia is detected based on a change in ST segment elevation combined with minimal change in the interval between the QRS complex and the end of the T-wave (QTend). Hypoglycemia is detected based on a change in ST segment elevation along with a lengthening of either QTmax or QTend. Hyperglycemia is detected based on a change in ST segment elevation along with minimal change in QTmax and in QTend. By exploiting QTmax and QTend in combination with ST segment elevation, changes in ST segment elevation caused by hypo/hyperglycemia can be properly distinguished from changes caused by ischemia.
    Type: Application
    Filed: April 11, 2012
    Publication date: August 2, 2012
    Applicant: PACESETTER, INC.
    Inventors: Jong Gill, Peter Boileau, Rupinder Bharmi, Xiaoyi Min, Joseph J. Florio, Michael E. Benser, Gene A. Bornzin
  • Publication number: 20120190957
    Abstract: A method of monitoring progression of cardiac disease includes applying stimulus pulses to the heart and sensing electrophysiological responses of the heart at a plurality of different monitoring locations of the heart. The method also includes comparing a previously and subsequently sensed electrophysiological responses that are sensed near a first location of the monitoring locations and comparing previously and subsequently sensed electrophysiological responses that are sensed near a second location of the monitoring locations. The method further includes identifying a change in progression of cardiac disease of the heart based on a difference between the previously and subsequently sensed electrophysiological responses at the first location and based on a difference between the previously and subsequently sensed electrophysiological responses at the second location.
    Type: Application
    Filed: January 20, 2011
    Publication date: July 26, 2012
    Applicant: PACESETTER, INC.
    Inventors: Jong Gill, Cecilia Qin Xi, Stuart Rosenberg, Yelena Nabutovsky, Brian Jeffrey Wenzel, William Hsu
  • Publication number: 20120165884
    Abstract: Provided herein are implantable systems, and methods for use therewith, for monitoring a patient's fluid accumulation level. A thoracic impedance signal for the patient is obtained. Based on the thoracic impedance signal, a duration metric indicative of a duration of drop of the thoracic impedance signal, a magnitude metric indicative of a magnitude of drop of the thoracic impedance signal, and a rate metric indicative of a rate of drop of the thoracic impedance signal is determined. The patient's fluid accumulation level is monitored based on the duration metric, the magnitude metric and the rate metric.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 28, 2012
    Inventors: Cecilia Qin Xi, Stuart Rosenberg, Jong Gill, Yelena Nabutovsky, William Hsu, Brian Jeffrey Wenzel
  • Publication number: 20120158079
    Abstract: Techniques are provided for use with an implantable medical device for assessing left ventricular (LV) sphericity and atrial dimensional extent based on impedance measurements for the purposes of detecting and tracking heart failure and related conditions such as volume overload or mitral regurgitation. In some examples described herein, various short-axis and long-axis impedance vectors are exploited that pass through portions of the LV for the purposes of assessing LV sphericity. In other examples, impedance measurements taken along a vector between a right atrial (RA) ring electrode and an LV electrode implanted near the atrioventricular (AV) groove are exploited to assess LA extent, biatrial extent or mitral annular diameter. The assessment techniques can be employed alone or in conjunction with other heart failure detection techniques, such as those based on left atrial pressure (LAP.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 21, 2012
    Applicant: PACESETTER, INC.
    Inventors: Stuart Rosenberg, Yelena Nabutovsky, Cecilia Qin Xi, Jong Gill, Kyungmoo Ryu, Brian Jeffrey Wenzel, William Hsu
  • Patent number: 8180441
    Abstract: Techniques are described for detecting ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. Ischemia is detected based on a shortening of the interval between the QRS complex and the end of a T-wave (QTmax), alone or in combination with a change in ST segment elevation. Alternatively, ischemia is detected based on a change in ST segment elevation combined with minimal change in the interval between the QRS complex and the end of the T-wave (QTend). Hypoglycemia is detected based on a change in ST segment elevation along with a lengthening of either QTmax or QTend. Hyperglycemia is detected based on a change in ST segment elevation along with minimal change in QTmax and in QTend. By exploiting QTmax and QTend in combination with ST segment elevation, changes in ST segment elevation caused by hypo/hyperglycemia can be properly distinguished from changes caused by ischemia.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: May 15, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Jong Gill, Peter Boileau, Rupinder Bharmi, Xiaoyi Min, Joseph J. Florio, Michael E. Benser, Gene A. Bornzin
  • Patent number: 8180439
    Abstract: An implanted cardiac rhythm management device is disclosed that is operative to detect myocardial ischemia. This is done by evaluating electrogram features to detect an electrocardiographic change; specifically, changes in electrogram segment during the early part of an ST segment. The early part of the ST segment is chosen to avoid the T-wave.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: May 15, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Jong Gill, Peter Boileau, Gene A. Bornzin, Joseph J. Florio, Mohssen Fard
  • Patent number: 8162842
    Abstract: Methods and systems are presented for using an ICD to detect myocardial ischemia. One such method includes sensing via an implantable cardiac-rhythm-management device (ICRMD) a signal indicative of cardiac pressure; determining via a processor associated with the ICRMD, a derivative signal that is a first derivative of the sensed signal; measuring via the processor, a maximum positive value of the derivative signal; measuring via the processor, a maximum negative value of the derivative signal; and indicating via the processor, an ischemia based on a comparison of a ratio of the maximum positive value to the maximum negative value with a predetermined value.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: April 24, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Jong Gill, Peter Boileau, Gene A. Bornzin, Joseph J. Florio, Xiaoyi Min
  • Patent number: 8160700
    Abstract: An exemplary method includes delivering a cardiac pacing therapy using an electrode configuration for left ventricular, single site pacing or left ventricular, multi-site pacing, measuring a series of interventricular conduction delays using the left ventricular pacing and right ventricular sensing (IVCD-LR), comparing the interventricular conduction delay values to a limit and, based on the comparison, deciding whether to change the electrode configuration for the left ventricular pacing. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: April 17, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Kyungmoo Ryu, Jong Gill
  • Publication number: 20120065528
    Abstract: Provided herein are implantable systems, and methods for use therewith, for monitoring a patient's pre-ejection interval (PEI). A signal indicative of cardiac electrical activity and a signal indicative of changes in arterial blood volume are obtained. One or more predetermined features of the signal indicative of cardiac electrical activity and the signal indicative of changes in arterial blood volume are detected. The patient's PEI is determined by determining an interval between the predetermined feature of the signal indicative of cardiac electrical activity and the predetermined feature of the signal indicative of changes in arterial blood volume.
    Type: Application
    Filed: September 14, 2010
    Publication date: March 15, 2012
    Applicant: PACESETTER, INC.
    Inventors: Jong Gill, Brian Jeffrey Wenzel, Allen Keel, Wenbo Hou, Edward Karst, Taraneh G. Farazi
  • Publication number: 20120065527
    Abstract: Implanted systems and methods for monitoring a patient's arterial stiffness are provided. An implanted sensor is used to produce a signal indicative of changes in arterial blood volume for a plurality of beats of the patient's heart. A pulse duration metric is determined for each of a plurality of pulses of the signal, wherein each pulse of the signal corresponds to a beat of the patient's heart. Arterial stiffness is monitored based on the determined pulse duration metric for the plurality of pulses of the signal. This can include monitoring arterial stiffness based on a dispersion of the pulse duration metric and/or an average of the pulse duration metric.
    Type: Application
    Filed: September 14, 2010
    Publication date: March 15, 2012
    Applicant: PACESETTER, INC.
    Inventors: Jong Gill, Brian Jeffrey Wenzel, Allen Keel, Wenbo Hou, Edward Karst, Taraneh G. Farazi
  • Patent number: 8131361
    Abstract: An intrinsic inter-atrial conduction delay is determined by a pacemaker or implantable cardioverter-defibrillator based, at least in part, on far-field atrial events sensed using ventricular pacing/sensing leads. An atrioventricular pacing delay is then set based on the inter-atrial conduction delay. By detecting atrial events using ventricular leads, rather than using atrial leads, a more useful measurement of the intrinsic inter-atrial conduction delay can be obtained. In this regard, since atrial electrodes detect atrial activity locally around the electrodes, a near-field atrial event sensed using an atrial electrode might not properly represent the actual timing of the atrial event across both the right and left atria. Far-field atrial events sensed using ventricular leads thus allow for a more useful measurement of inter-atrial conduction delays for use in setting atrioventricular pacing delays.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: March 6, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Jong Gill, Gene A. Bornzin
  • Patent number: 8121675
    Abstract: Detection of atrial fibrillation involves detecting a plurality of ventricular events and obtaining a series of probabilities of AF, each corresponding to a probability of AF for a different beat window having a plurality of ventricular events. AF onset is detected when one or each of a plurality of consecutive AF probabilities satisfies an AF trigger threshold. AF termination is detected when one or each of a plurality of consecutive AF probabilities does not satisfy the AF trigger threshold. Upon detection of AF onset, ventricular events are processed to detect for a sudden onset of irregularity of the ventricular events. AF onset is confirmed when sudden onset is detected and overturned when sudden onset is not detected.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: February 21, 2012
    Assignee: Pacesetter, Inc.
    Inventors: Cem Shaquer, Jong Gill, Fujian Qu